| June 2012
One Powerful Weekend
The ABTA’s annual Patient and Family Conference—taking place July 27-29, 2012 in Chicago, IL—is a highlight not only for attendees, but for presenters as well. To hear what brain tumor experts from around the country have to say about this valuable event, click here, then visit www.braintumorconference.org to register. It’s one powerful weekend you won’t want to miss.
Understanding Proton Therapy
“Understanding Proton Therapy,” the first in a series of free American Brain Tumor Association webinars, is scheduled for Friday, June 22, at 1:00 p.m., CST. Anita Mahajan, M.D., medical director of the MD Anderson Proton Therapy Center, is the featured presenter. The program includes an online Q&A session with Dr. Mahajan. To register, go to http://bit.ly/protontherapywebinar.
Website Highlight: Share Your Story
The debut of the new www.abta.org comes with exciting interactive features. One of our favorites is “Share Your Story.” Here, you’re able to share your own or your loved one’s story about their brain tumor journey. Click here to share your story and read the stories of other brain tumor patients and families.
ABTA in Action
The ABTA Patient Services team took part in two recent professional conferences: the Association of Oncology Social Work Annual Conference in Boston (May 30 – June 1) and the American Society of Clinical Oncology Annual Conference in Chicago (June 1 - 4). With in-depth sessions covering clinical trials, treatments, quality of life studies, survivorship care needs, social worker roles and skills, the conferences keep the ABTA up-to-date with the latest in brain tumor research and care trends, which we are in turn able pass on to you.
Survival and Long-Term Impact of Benign Meningioma
It has only recently been recognized that meningiomas now constitute 33%-50% of newly diagnosed primary brain tumors, and patients with meningioma represent the vast majority of long-term brain tumor survivors. A study of 205 patients in the Netherlands with WHO grade I meningioma found survival at five, 10, 15, and 20 years to be 92%, 81%, 63%, and 53%, respectively. Recurrence rates at five, 10 and 15 years were 18%, 26% and 32%, respectively. Long-term functioning (five or more years after last treatment) was assessed in 89 long-term survivors: 29 patients (33%) showed no deficits, and 60 (67%) showed at least one neurological symptom. The research was reported in the May 2012 Neuro-oncology. Click here to read a summary of the other findings.
Tumor Removal in Oligodendroglial Tumors
Although oligodendrogliomas that enhance (take up the contrast dye) on MRI may be associated with poor prognosis, scientists have been unclear as to the importance of the volume of enhancing tumor both before and after resection. The authors of the article, “Magnetic Resonance Imaging Volumetric Assessment of the Extent of Contrast Enhancement and Resection in the Oligodendroglial Tumors,” published in the June 2012 Journal of Neurosurgery, looked back at 100 cases of oligodendroglioma involving patients that had undergone MRI at diagnosis and immediately after initial surgical intervention. They found that when 100% of the enhancing tumor was able to be removed, the time to tumor regrowth and overall survival time was significantly extended. They also found no correlation with the presence/absence of 1p/19q deletions. To read the abstract, click here.
GBM and Pregnancy
Glioblastoma multiforme diagnosed during pregnancy presents unique challenges for clinicians because there are few standard guidelines for treating patients within the context of pregnancy. Treatment planning must balance potential benefits to the mother against any risk to the fetus. The article “Management of Glioblastoma Multiforme in Pregnancy,” in the June 2012 Journal of Neurosurgery, examines the role, safety and timing of radiotherapy, chemotherapy, timing of surgery, anesthetic considerations, postoperative care, and the use of essential medications for GBM during pregnancy. Click here to read the abstract.
Identifying how caregivers initially perceive the benefits and rewards of caregiving is vital to helping family caregivers maintain their emotional health and potentially improving the quality of patient care delivered in the home. A recent study of family caregivers’ perceptions of the positive aspects of caring (PAC) from the time of diagnosis to four months following diagnosis found that PAC scores during the first four months appeared to remain stable over time. The authors, reporting in the June 2012 Oncology Nursing Society, recognized that caregiver perceptions may be related to the patient’s level of functioning. The study encourages clinicians to seek out caregivers who may be at risk for negative outcomes, and suggests that future research might focus on developing interventions for caregivers who report low levels of PAC at the time of diagnosis. A summary of the study can be found by clicking here.
You Oughta Be in Pictures…
Were you one of the 4,500+ people who helped us raise nearly $900,000 at the Breakthrough for Brain Tumors 5K on May 12? It may have been a bit soggy, but we still had a great time. Check out the photo links here.
Breaking Through in NYC
Registration for the New York City Breakthrough for Brain Tumors 5K Run/Walk is now open. The event takes place on Saturday, November 10 at Hudson River Park’s Pier 84. To register, visit www.breakthroughforbraintumors.org.
Host Your Own Fundraising Event
Host your own fundraising event to honor a loved one and support the American Brain Tumor Association. Join hundreds of others around the country who are putting on their own volunteer fundraising events on behalf of the ABTA. Click here to learn more about what you can do, email email@example.com.
We Want You for 26.2
Team Breakthrough has just seven bibs left for the Bank of America Chicago Marathon. Training has just started and it isn’t too late to register. Visit www.abtateambreakthrough.org to join.
Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. For nearly 40 years, the Chicago-based ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care.
Make a donation to the American Brain Tumor Association.
This information is provided by the American Brain Tumor Association, 8550 W. Bryn Mawr Ave., Suite 550, Chicago, IL 60631. For more information about the American Brain Tumor Association, call toll-free 866-659-1030, write firstname.lastname@example.org or visit www.abta.org.
"American Brain Tumor Association" and "TrialConnect" are registered trademarks of the American Brain Tumor Association. The ABTA logo, the "Breakthrough for Brain Tumors" name and logo, and the "Team Breakthrough" name and logo are trademarks of the American Brain Tumor Association. All rights reserved.
Update Email Preferences | Forward to a Friend | Unsubscribe
©2012 American Brain Tumor Association
Having Fun Raising Funds
To learn more about our events visit www.abta.org/events.
8th Annual Head for the Cure
June 9, 2012
Sharing Hope - Walk the Walk, Talk the Talk
June 9, 2012
Jerry Hoyt Memorial Cancer Walk
July 7, 2012
7th Annual Teeing Up for Others
July 20, 2012
Columbia Station, OH
Paul Fabbri Memorial Golf Classic
September 22, 2012
Breakthrough for Brain Tumors NYC 5K Run/Walk
November 10, 2012
New York, NY
The ABTA's Connections links patients, families, friends, caregivers and health care professionals with each other for support and inspiration. The online community is a safe place to visit, join and interact with members of the brain tumor community nationally and around the world.
Find a Clinical Trial Through Trial Connect
The ABTA's TrialConnect, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Read more.
Our Care Consultants provide brain tumor information, support and education for patients, families and health care professionals. Write email@example.com or call our toll-free CareLine at 800-886-ABTA (2282).